Dolph Lundgren Open Up About His Kidney Cancer Journey

Hollywood action star Dolph Lundgren revealed that doctors initially missed a critical genetic mutation that could have changed the course of his kidney cancer treatment. The actor, best known for roles in Rocky IV and The Expendables, was diagnosed with renal cell carcinoma in 2015 and faced a recurrence in 2020, only to discover that a key ALK mutation was overlooked during early testing. Lundgren's candid disclosure highlights a systemic gap in oncological care and underscores the life-saving potential of comprehensive genetic profiling.

Lundgren, now 68, shared his decade-long battle with kidney cancer in a recent interview. He was first diagnosed with renal cell carcinoma, the most common form of kidney cancer, in 2015. After successful treatment, the cancer returned in 2020, prompting a deeper investigation into his tumor's biology. It was then that doctors identified an ALK (anaplastic lymphoma kinase) gene mutation—a targetable abnormality that had been present from the start but was missed in initial testing.

The missed ALK mutation is significant because it opens the door to targeted therapies. Drugs such as crizotinib and alectinib are designed to block ALK-driven cancer growth and are now standard for certain lung cancers but are less commonly considered for kidney cancer. Lundgren's case illustrates how genomic sequencing can uncover actionable mutations even in less typical cancers.

Lundgren's cancer journey also reflects broader trends in oncology. Precision medicine is increasingly dependent on comprehensive genomic profiling, yet many patients still receive only basic testing. According to the American Cancer Society, renal cell carcinoma accounts for about 3% of all cancers, and while early-stage disease has a high survival rate, advanced cases often require novel approaches. ALK mutations are rare in kidney cancer—occurring in fewer than 1% of cases—but when present, they can fundamentally alter treatment strategy.

The actor's decision to go public with his medical history serves as both a cautionary tale and a call to action. Experts in cancer genetics emphasize that second opinions and repeat biopsies can catch what initial screens miss. Lundgren himself has become an advocate for broader genetic testing, arguing that no patient should assume their first diagnosis is the final word.

Looking ahead, Lundgren remains cancer-free as of mid-2025, but his experience has reshaped how he approaches health. The Dolph Lundgren kidney cancer story is now a living case study in the importance of persistence and precision. For the medical community, it reinforces the need to standardize genomic testing in oncology, especially when standard treatments fail. Lundgren's victory over the disease is personal, but the lessons are universal: never overlook the small mutations that can make the biggest difference.